We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$9.32B
AUM Growth
+$2.47B
Cap. Flow
+$393M
Cap. Flow %
4.22%
Top 10 Hldgs %
43.12%
Holding
161
New
36
Increased
24
Reduced
14
Closed
22

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$348M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$229M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$100M
4
CCCC icon
C4 Therapeutics
CCCC
+$91.6M
5
KRON
Kronos Bio
KRON
+$87.2M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$190M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$112M
3
IMMU
Immunomedics Inc
IMMU
+$77.6M
4
BPMC
Blueprint Medicines
BPMC
+$61.6M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 85.2%
2 Financials 0.33%
3 Industrials 0.29%
4 Materials 0.22%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$811M 8.71%
3,693,516
+257,941
+8% +$55.8M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$580M 6.22%
25,112,048
-10,000
-0% -$205K
BBIO icon
3
BridgeBio Pharma
BBIO
$16.5B
$477M 5.12%
6,706,268
– –
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.02B
$425M 4.56%
9,166,304
-919,328
-9% -$36.5M
NVTA
5
DELISTED
Invitae Corporation
NVTA
$305M 3.27%
+7,284,466
New +$348M
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$303M 3.25%
4,177,721
+696,573
+20% +$44.8M
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
$246M 2.64%
5,674,711
-126,285
-2% -$6.23M
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$226M 2.42%
+3,084,042
New +$229M
ZYME icon
9
Zymeworks
ZYME
$1.62B
$203M 2.18%
4,300,999
-100,000
-2% -$4.64M
RCKT icon
10
Rocket Pharmaceuticals
RCKT
$333M
$186M 2%
3,396,867
+1,207,857
+55% +$44M
NBIX icon
11
Neurocrine Biosciences
NBIX
$18.2B
$182M 1.95%
1,899,215
+350,500
+23% +$33.9M
NVRO
12
DELISTED
NEVRO CORP.
NVRO
$169M 1.82%
977,565
+151,401
+18% +$24.5M
OM icon
13
Outset Medical
OM
$86.8M
$162M 1.74%
189,855
– –
VBIV
14
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$151M 1.62%
1,834,749
– –
ATNX
15
DELISTED
Athenex, Inc. Common Stock
ATNX
$150M 1.61%
676,623
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$362M
$130M 1.39%
+3,109,224
New +$100M
NVAX icon
17
Novavax
NVAX
$1.2B
$116M 1.25%
1,043,000
+335,285
+47% +$35.6M
KRRO icon
18
Korro Bio
KRRO
$144M
$115M 1.23%
65,193
+63
+0.1% +$83.2K
KOD icon
19
Kodiak Sciences
KOD
$2.44B
$110M 1.18%
751,533
-291,488
-28% -$32.5M
LONA
20
LeonaBio Inc
LONA
$65.1M
$107M 1.14%
311,481
– –
MGTX icon
21
MeiraGTx Holdings
MGTX
$1.07B
$105M 1.13%
6,933,277
+500,000
+8% +$7.07M
CCCC icon
22
C4 Therapeutics
CCCC
$389M
$105M 1.12%
+3,158,566
New +$91.6M
RLAY icon
23
Relay Therapeutics
RLAY
$3.96B
$96.8M 1.04%
2,329,407
– –
TVTX icon
24
Travere Therapeutics
TVTX
$5.13B
$95.2M 1.02%
3,493,607
+253,495
+8% +$5.92M
EIDX
25
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$90.4M 0.97%
686,922
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Perceptive Advisors held 161 positions worth $9.32B, up 36% from $6.85B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors deployed $393M of net new capital in Q4 2020, opening 36 new positions and adding to 24 existing holdings. Its largest new stake was Invitae Corporation: 7,284,466 shares worth $305M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $36.5M trimmed.

  • Perceptive Advisors's largest Q4 2020 buy was Invitae Corporation: 7,284,466 shares worth $305M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2020, an estimated $55.8M increase.
  • Perceptive Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $36.5M.
  • Perceptive Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $190M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $9.32B portfolio in Q4 2020.
  • Perceptive Advisors opened 36 new positions and closed 22 in Q4 2020.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $9.32B.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.